Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT02925221 is registered in ClinicalTrials.gov with Otsuka Canada Pharmaceutical Inc. as lead sponsor.

NCT NCT02925221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02925221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Lead sponsor
Otsuka Canada Pharmaceutical Inc.
Phase
Observational
Overall status
Completed
Start date
February 26, 2016
Completion date
December 31, 2025
Enrollment
530 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease (adpkd)